Addiction Therapeutix

Addiction Therapeutix is focused on the development of compounds for Co-Morbid Alcoholism and Anxiety and Opioid and Nicotine Addiction.

We hypothesize that our novel mixed agonist-antagonist aza-beta carboline compounds can help in the treatment of both alcoholism and the negative states associated with termination of chronic drinking. In addition, animal studies indicate that dextro-morphine given either systemically or intracerebrally blocks the reinforcement effect produced by morphine or nicotine and could be developed as a therapeutic treatment for opiate and nicotine addictions.

Addiction Therapeutix has a license agreement and relationship with University of Wisconsin-Milwaukee Research Foundation on a family of compounds for treating Co-morbid Alcoholism and Anxiety. The company also has an exclusive Option Agreement with the Medical College of Wisconsin for the potential use of dextro-morphine in treating opioid and nicotine addiction.

---

Video to the left:

The human brain is composed of approximately 100 billion hair-like nerve cells or neurons which receive, integrate, conduct and transmit electrochemical signals. Attenuation of specific chemicals in the brain and disruption of reward circuits is implicated in drug addiction. 3D animation above depicts neuronal network sending electrical impulses and communicating with neighboring neurons during processing of information.